Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glp-1-fc fusion protein formulation

A fusion protein and glp-1-fc technology, applied in peptide/protein components, drug combinations, medical preparations of non-active ingredients, etc., can solve problems such as unsuitable preparations

Inactive Publication Date: 2010-06-09
ELI LILLY & CO
View PDF3 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In addition, the preparation may not be suitable if it is physically unstable when there is instability caused by host cell proteases under examination

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glp-1-fc fusion protein formulation
  • Glp-1-fc fusion protein formulation
  • Glp-1-fc fusion protein formulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0026] In vitro GLP-1 receptor activation assay

[0027] Using the CRE-luciferase system, HEK-293 cells stably expressing the human GLP-1 receptor were seeded in 96-well plates at 30,000 cells / well / 80 μL DMEM F12 medium with low serum. One day after seeding, 20 [mu]L aliquots of test proteins dissolved in 0.5% BSA were mixed with cells and incubated for 5 hours. For each test protein, 12 dilutions containing 3pM to 3nM were prepared typically at a 5X concentration and added to the cells to generate a dose response curve from which the EC was determined. 50 value. After incubation, 100 μL of luciferase reagent was added directly to each plate and mixed gently for 2 minutes. The plate was placed in a Tri-lux luminometer and the light output due to luciferase expression was calculated.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders.

Description

field of invention [0001] The present invention relates to commercially available formulations of glucagon-like peptide analogs fused to the Fc portion of an immunoglobulin. The formulation can be used to treat diabetes and obesity, as well as a variety of other conditions or disorders. Background of the invention [0002] Glucagon-like peptide-1 (GLP-1) analogs and derivatives are promising in clinical trials for the treatment of type 2 diabetes. GLP-1 induces various biological effects such as stimulation of insulin secretion, inhibition of glucagon secretion, inhibition of gastric emptying, inhibition of gastric or intestinal motility, and induction of weight loss. A distinctive feature of GLP-1 is its ability to stimulate insulin secretion without the associated risks of hypoglycemia seen with insulin therapy or certain types of oral therapy that act by increasing insulin expression. [0003] GLP-1(1-37) activity is very low, and GLP-1(7-37)OH and GLP-1(7-36)NH 2 The ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/08A61K47/26A61K38/26
CPCA61K9/0019A61K47/26A61K47/18A61K38/26A61K47/12A61P3/10A61P3/04
Inventor K·额
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com